MucoLife Therapeutics secures €91K from Vinnova to scale manufacturing of COPD treatment. The funding will support the establishment of a scalable manufacturing process for MLT-001.
Amount Raised
€91,000
Round Type
Grant
Investors
Description
MucoLife Therapeutics has received €91,000 (SEK 1 million) from Vinnova, Sweden’s innovation agency, to develop a scalable manufacturing process for MLT-001, a therapy for chronic obstructive pulmonary disease (COPD). This grant will help in the purification process and advance the treatment closer to clinical trials. The company aims to achieve a suitable level of purity at a documented yield, in collaboration with a CDMO partner. This funding is crucial for turning MLT-001 into a viable medicine.
Who to call at MucoLife Therapeutics, and when
A new round usually means MucoLife Therapeutics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day MucoLife Therapeutics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at MucoLife Therapeutics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at MucoLife Therapeutics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment MucoLife Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
MucoLife Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.